1) FDA approves cancer treatment that uses virus to attack tumors – Boston Globe, 10/27/2015
Approved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus — called Imlygic, which was developed in part in a Massachusetts lab — is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.
2) King Street to build new lab building in the ‘next Kendall Square’ – BBJ, 10/27/2015
In a show of confidence in the continued growth of the biotech industry outside Cambridge, a Cambridge real estate firm is building what it says will be the biggest “on-spec” lab space ever seen in Boston’s suburbs.
3) Vertex puts $105 million into gene editing startup – Boston Globe, 10/26/2015
Vertex Pharmaceuticals Inc. is betting on a hot new technique in drug development to expand its cystic fibrosis pipeline and move into new treatment areas.The Boston company said Monday that it struck a $105 million cash and equity deal with CRISPR Therapeutics, a Swiss startup in the emerging field of gene editing.
4) Top women in biopharma 2015 – FierceBiotech, 10/28/2015
This year’s fiercest women in biopharma are seemingly doing it all. Pioneering a fully integrated biotech in China? Check. Leading aging research at Google’s mysterious new life sciences upstart? Check. Changing the game for biotech innovators? Running the world’s largest consumer health player? Blazing the off-P&L financing trail? Check, check, check.
5) Viewpoint: Why cost controls will undermine innovation, healthy outcomes – BBJ, 10/23/2015
Massachusetts’ companies are tackling some of the most difficult scientific challenges of our time, and we should continue to encourage the risk-taking and discovery we’re known for. Legislating drug pricing or instituting caps will undermine the recent economic and scientific growth the Commonwealth has seen, and will negatively impact patients.
1) Industry officials talk drug costs, disclosure at Mass. biotech caucus – State House News, 10/1/2015
Biotechnology experts on Thursday agreed that high cost of developing medications must be addressed, but said legislation to require disclosure of development costs is not the solution.
2) FierceBiotech’s 2015 Fierce 15 – FierceBiotech, 9/30/2015
Whatever lies ahead for biotech in 2016, we can now look back on a 3-year-long stretch of good times for the industry. Venture groups have used the wave of biotech IPO exits and M&A deals to go back and raise more money from institutional investors. And as billions of dollars in fresh capital has converged with brilliant new scientific thinking, the result is a whole new wave of standout innovators as represented here by the Fierce 15.
3) FDA Approves Bristol-Myers’s Yervoy, Opdivo for Treatment of Melanoma – WSJ, 10/1/2015
The U.S. Food and Drug Administration approved the first therapy combining two cutting-edge cancer drugs that unleash the body’s immune system against tumors—a combination that will cost more than $250,000 per patient for the first full year, according to its manufacturer.
4) Cambridge drug firm Infinity earns $130 million milestone from AbbVie – BBJ, 9/30/2015
Infinity Pharmaceuticals announced today that the company has enrolled the 120th, and final, patient into a mid-stage study involving patients with a form of blood cancer, resulting in a payout that doubles its cash on hand.
5) Third Rock launches cancer-fighting startup – Boston Globe, 10/1/2015
Third Rock Ventures, a prominent Boston life sciences investor, has launched a cancer-fighting startup with funding from two other investors.